| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Bis-PEG3-NHS ester is a non-cleavable 3-unit PEG linker used in antibody-drug conjugation (ADC). Its primary targets are the primary amines (-NH2) of proteins and amine-modified oligonucleotides. The compound is instrumental in the creation of stable conjugates for a variety of applications, from fundamental research to the development of advanced therapeutics like antibody-drug conjugates (ADCs). Its PEG3 spacer enhances solubility, reduces immunogenicity, and enables controlled drug loading on antibodies. The compound is widely used in protein-protein crosslinking, antibody modification, and surface functionalization.
|
|---|---|
| ln Vitro |
In vitro, Bis-PEG3-NHS ester is used for efficient crosslinking of proteins via primary amines. Its PEG3 spacer enhances solubility, reduces immunogenicity, and enables controlled drug loading on antibodies. The compound's reactivity is pH-dependent, with the optimal pH range for the reaction with primary amines between 7.0 and 8.5. The stability of NHS esters in aqueous solutions is a critical consideration for experimental design; the half-life of the NHS ester moiety is highly dependent on the pH of the solution. Bis-PEG3-NHS ester is widely used in bioconjugation, chemical biology, and drug delivery system development.
|
| ln Vivo |
In vivo, Bis-PEG3-NHS ester is used in the construction of ADCs that facilitate the delivery of cytotoxic payloads to specific cells. ADCs are comprised of an antibody to which a cytotoxic payload is attached through the linker. The non-cleavable nature of the PEG3 linker ensures that the conjugate remains intact until it is internalized by the target cell and degraded in the lysosome. The PEG spacer in Bis-PEG3-NHS ester enhances solubility and reduces immunogenicity of the resulting conjugates. The compound is a research tool for the development of ADCs and other targeted therapies.
|
| Enzyme Assay |
In vitro protein crosslinking assays involve reacting the NHS ester with primary amines on proteins, followed by analysis via SDS-PAGE or mass spectrometry to confirm conjugation. The assay is conducted by incubating the protein with varying concentrations of Bis-PEG3-NHS ester in a buffer at pH 7.0-8.5. The reaction is typically carried out at room temperature for 1-2 hours, and the extent of conjugation is assessed by the shift in molecular weight on SDS-PAGE or by MALDI-TOF mass spectrometry. The conjugation efficiency is calculated based on the ratio of conjugated to unconjugated protein.
|
| Cell Assay |
In vitro cell-based assays evaluate the efficacy of ADCs constructed with Bis-PEG3-NHS ester in cancer cell lines, measuring cytotoxicity and target specificity. Cancer cells are cultured in appropriate media and treated with serial dilutions of the ADC. Cell viability is assessed using MTT or CellTiter-Glo assays after 48-72 hours of treatment. The IC50 values for cytotoxicity are calculated. Target specificity is evaluated by comparing the cytotoxicity of the ADC in target-positive versus target-negative cell lines. Flow cytometry is used to assess ADC binding and internalization.
|
| Animal Protocol |
In vivo, ADCs constructed with Bis-PEG3-NHS ester are evaluated in xenograft mouse models of cancer. Immunocompromised mice bearing subcutaneous tumors are treated with the ADC via intravenous injection at various doses. Tumor volume is measured twice weekly using calipers, and tumor growth inhibition (TGI) is calculated relative to vehicle-treated controls. Pharmacokinetic studies are conducted to determine the ADC's half-life, clearance, and tissue distribution. The safety profile of the ADC is assessed by monitoring body weight, clinical signs, and hematological parameters.
|
| ADME/Pharmacokinetics |
Bis-PEG3-NHS ester is a non-degradable linker containing 3 PEG units that may be utilized to prepare active ADCs. The PEG spacer enhances solubility and reduces immunogenicity of the resulting conjugates. The compound has a spacer arm length of 14.6 Å (13 atoms) and a purity of >98%. It is soluble in water, methylene chloride, acetonitrile, methanol, DMAC, and DMSO. The compound should be stored at -20°C, desiccated, and allowed to reach room temperature before opening.
|
| Toxicity/Toxicokinetics |
The toxicity of Bis-PEG3-NHS ester is primarily associated with its reactivity as a crosslinking agent. The compound can cause skin and eye irritation upon contact. Inhalation of the compound may cause respiratory irritation. In preclinical studies, the compound has shown low acute toxicity, but its reactivity with proteins raises concerns about potential off-target effects. The compound should be handled with appropriate personal protective equipment in a well-ventilated area. For research use only, not for human use.
|
| Additional Infomation |
Bis-PEG3-NHS ester is a non-cleavable 3-unit PEG linker used in antibody-drug conjugation (ADC). It is a homobifunctional crosslinker instrumental in the creation of stable conjugates for applications ranging from fundamental research to the development of advanced therapeutics like ADCs. The PEG3 spacer enhances solubility, minimizes aggregation, and provides flexibility to improve conjugate stability. Bis-PEG3-NHS ester is widely used in protein-protein crosslinking, antibody modification, and surface functionalization. It is a research tool for bioconjugation, chemical biology, and drug delivery system development.
|
| Molecular Formula |
C18H24N2O11
|
|---|---|
| Molecular Weight |
444.3900
|
| Exact Mass |
444.138
|
| CAS # |
1314378-16-9
|
| PubChem CID |
57673804
|
| Appearance |
White to off-white solid powder
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
31
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC(=O)N(C1=O)OC(=O)CCOCCOCCOCCC(=O)ON2C(=O)CCC2=O
|
| InChi Key |
OPGNUERFYQLUNP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H24N2O11/c21-13-1-2-14(22)19(13)30-17(25)5-7-27-9-11-29-12-10-28-8-6-18(26)31-20-15(23)3-4-16(20)24/h1-12H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2503 mL | 11.2514 mL | 22.5028 mL | |
| 5 mM | 0.4501 mL | 2.2503 mL | 4.5006 mL | |
| 10 mM | 0.2250 mL | 1.1251 mL | 2.2503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
